Back to results
US 2021/0059960 A1Published application
Pharmaceutical composition comprising a cannabinoid
AssigneeGW Research Limited
InventorsJitinder WILKHU, Johan BENDER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation is contained in a container. By Type IV-like, it is meant that the formulation comprises no oil, for example no triglycerides or mixed glycerides.
Claims33
An oral pharmaceutical formulation comprising:
- at least one cannabinoid;
- at least one poloxamer;
- and
- a solvent, wherein the solvent is defined according to formula (I)
- wherein R1 and R2 are independently selected from hydrogen, C(O)CH3, OH, C(O)CH3, CH2OH and C(O)OCH2CH3;
- R3 is independently selected from CH3, CH2OH, OH, CH2OC(O)CH3 and CH2C(O)CH2CH3;
- and R4 is independently selected from hydrogen and C(O)OCH2CH3;
- wherein the oral pharmaceutical formulation is contained in a container.
5 more elements
9-10. (canceled)
(canceled)
30-34. (canceled)
38-40. (canceled)
Dependencies are inferred from the claim text.